MTOR and acute myeloid leukemia: Targeting of mTOR signaling has also been investigated in AML, Ph+ALL, and T-ALL [120,147,155,156,157], and has led to a phase I clinical trial with NVP-BEZ235 for dose-escalations and relapsed or refractory AML (NCT01756118).